MEDI-507

TERMINATED · PHASE1 · Lymphoproliferative Disorders

After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.